Related Experiment Video
Updated: Oct 10, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo
Aurélie Moniot1,2, Julien Braux1,2, Camille Bour1
1EA 4691 Biomatériaux & Inflammation en Site Osseux (BIOS), SFR CAP-Santé (FED 4231), Université de Reims Champagne-Ardenne, 51 Rue Cognacq Jay, 51096 Reims, France.
Abstract:
Osteosarcoma is a rare primary bone cancer that mostly affects children and young adults. Current therapeutic approaches consist of combining surgery and chemotherapy but remain unfortunately insufficient to avoid relapse and metastases. Progress in terms of patient survival has remained the same for 30 years. In this study, novel pyridazinone derivatives have been evaluated as potential anti-osteosarcoma therapeutics because of their anti-type 4 phosphodiesterase activity, which modulates the survival of several other cancer cells. By using five-four human and one murine osteosarcoma-cell lines, we demonstrated differential cytotoxic effects of four pyridazinone scaffold-based compounds (mitochondrial activity and DNA quantification). Proapoptotic (annexin V positive cells and caspase-3 activity), anti-proliferative (EdU integration) and anti-migratory effects (scratch test assay) were also observed. Owing to their cytotoxic activity in in vitro conditions and their ability to limit tumor growth in a murine orthotopic osteosarcoma model, our data suggest that these pyridazinone derivatives might be hit-candidates to develop new therapeutic strategies against osteosarcoma.
Insights
Novel pyridazinone derivatives show promise as new osteosarcoma treatments. These compounds demonstrated significant anti-cancer effects in laboratory studies and animal models, offering hope for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Osteosarcoma is a rare bone cancer primarily affecting young individuals.
- Current treatments (surgery, chemotherapy) have limited efficacy, leading to frequent relapses and metastases.
- Patient survival rates for osteosarcoma have stagnated for three decades.
Purpose of the Study:
- To evaluate novel pyridazinone derivatives as potential anti-osteosarcoma therapeutics.
- To investigate the anti-type 4 phosphodiesterase activity of these compounds.
- To explore their potential in overcoming current therapeutic limitations.
Main Methods:
- Utilized five human and one murine osteosarcoma cell lines.
- Assessed compound cytotoxicity via mitochondrial activity and DNA quantification.
- Evaluated pro-apoptotic, anti-proliferative, and anti-migratory effects.
- Tested efficacy in a murine orthotopic osteosarcoma model.
Main Results:
- Demonstrated differential cytotoxic effects of four pyridazinone derivatives.
- Observed significant pro-apoptotic, anti-proliferative, and anti-migratory activities.
- Confirmed tumor growth limitation in an in vivo murine model.
Conclusions:
- Pyridazinone derivatives exhibit potent anti-osteosarcoma activity in vitro and in vivo.
- These compounds show potential as hit-candidates for developing novel therapeutic strategies.
- Further research is warranted to translate these findings into clinical applications for osteosarcoma treatment.
